Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

[1]  A. Taguchi,et al.  Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid , 2019, Journal of Bone and Mineral Metabolism.

[2]  S. Dry,et al.  Development of Medication-Related Osteonecrosis of the Jaw After Extraction of Teeth With Experimental Periapical Disease. , 2019, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[3]  S. Mallya,et al.  Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws. , 2018, Oral surgery, oral medicine, oral pathology and oral radiology.

[4]  N. Park,et al.  Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice. , 2018, The American journal of pathology.

[5]  T. Shibahara,et al.  National Survey on Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. , 2018, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[6]  S. Ivanovski,et al.  Risk factors for medication-related osteonecrosis of the jaws: A systematic review. , 2018, Oral diseases.

[7]  M. Elsalanty,et al.  Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. , 2018, Bone.

[8]  H. Devlin,et al.  Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis , 2017, BDJ.

[9]  Ç. Karaca,et al.  The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw. , 2017, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[10]  P. Shah,et al.  Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. , 2017, Journal of the American Dental Association.

[11]  E. Itoi,et al.  A Strategy against the Osteonecrosis of the Jaw Associated with Nitrogen-Containing Bisphosphonates (N-BPs): Attempts to Replace N-BPs with the Non-N-BP Etidronate. , 2016, Biological & pharmaceutical bulletin.

[12]  R. Seemann,et al.  The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection , 2016, Scientific Reports.

[13]  K. Kaur,et al.  Plasticity of Myeloid Cells during Oral Barrier Wound Healing and the Development of Bisphosphonate-related Osteonecrosis of the Jaw* , 2016, The Journal of Biological Chemistry.

[14]  K. Błażewska,et al.  Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine. , 2016, Bioconjugate chemistry.

[15]  Smita Jha,et al.  Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996–2012: An Ecological Analysis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  O. Nicolatou‐Galitis,et al.  Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[17]  S. Tetradis,et al.  Pathophysiology of Osteonecrosis of the Jaws. , 2015, Oral and maxillofacial surgery clinics of North America.

[18]  S. Dry,et al.  OPG‐Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: Role in osteoclast-mediated NK cell activation , 2015, Oncotarget.

[20]  Jun Wang,et al.  Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw , 2015, Journal of Translational Medicine.

[21]  J. Sayre,et al.  Osteonecrosis of the Jaw Developed in Mice , 2015, The Journal of Biological Chemistry.

[22]  Jacques P. Brown,et al.  Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  A. Goss,et al.  A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[24]  G. Lamas,et al.  Quality-of-Life Outcomes With a Disodium EDTA Chelation Regimen for Coronary Disease: Results From the Trial to Assess Chelation Therapy Randomized Trial , 2014, Circulation. Cardiovascular quality and outcomes.

[25]  S. Dry,et al.  Stage 0 osteonecrosis of the jaw in a patient on denosumab. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[26]  T. Zeinoun,et al.  Bisphosphonate Related Osteonecrosis of the Jaw: A Study of 18 Cases Associated with Fungal Infection , 2014, International journal of dentistry.

[27]  Y. Kao Yang,et al.  Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population , 2014, Osteoporosis International.

[28]  T. Kofod,et al.  Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. , 2014, Oral surgery, oral medicine, oral pathology and oral radiology.

[29]  S. Dry,et al.  Periapical Disease and Bisphosphonates Induce Osteonecrosis of the Jaws in Mice , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  N. Watts,et al.  Bisphosphonate drug holiday: who, when and how long , 2013, Therapeutic advances in musculoskeletal disease.

[31]  A. Hokugo,et al.  Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats. , 2013, Bone.

[32]  E. Marcantonio,et al.  Experimental development of bisphosphonate‐related osteonecrosis of the jaws in rodents , 2013, International journal of experimental pathology.

[33]  D. Kimmel,et al.  Oncologic doses of zoledronic acid induce osteonecrosis of the jaw‐like lesions in rice rats (Oryzomys palustris) with periodontitis , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  K. Rothman,et al.  Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis , 2012, Pharmacoepidemiology and drug safety.

[35]  L. Ciuffreda,et al.  Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Y. Kitagawa,et al.  Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. , 2011, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[37]  S. Dry,et al.  Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  A. Boyde,et al.  The relationship between the chemistry and biological activity of the bisphosphonates. , 2011, Bone.

[39]  S. Puzzo,et al.  Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. , 2011, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[40]  M. Allen,et al.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing , 2011, Odontology.

[41]  P. Vescovi,et al.  Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. , 2010, The American journal of medicine.

[42]  D. Hatcher,et al.  Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[43]  H. Kawamura,et al.  Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[44]  J. Sayre,et al.  Increased Prevalence of Bisphosphonate-Related Osteonecrosis of the Jaw with Vitamin D Deficiency in Rats , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  M. Rogers,et al.  Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. , 2008, Bioconjugate chemistry.

[46]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[47]  M. Boccadoro,et al.  Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates , 2008, Leukemia & lymphoma.

[48]  T. Hansen,et al.  Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis , 2007, Virchows Archiv.

[49]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  P. Moss,et al.  Immunodeficiency and immunotherapy in multiple myeloma , 2007, British journal of haematology.

[51]  T. Kawamoto,et al.  Use of a new adhesive film for the preparation of multi-purpose fresh-frozen sections from hard tissues, whole-animals, insects and plants. , 2003, Archives of histology and cytology.

[52]  L. Hothorn,et al.  Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. , 2002, The Journal of rheumatology.

[53]  M. Horton,et al.  Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and Macrophages* , 2001, The Journal of Biological Chemistry.

[54]  C. Löwik,et al.  Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. , 1998, Bone.

[55]  J. Bevan,et al.  Comparative evaluation of three diphosphonates: in vitro adsorption (C- 14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  M. Zandi,et al.  The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study. , 2017, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[57]  T. Dodson,et al.  Medication-Related Osteonecrosis of the Jaw—2014 Update , 2014 .

[58]  M. Heiland,et al.  Pseudoepitheliomatous hyperplasia associated with bisphosphonate-related osteonecrosis of the jaw. , 2014, In vivo.

[59]  S. Kousteni,et al.  Annals of the New York Academy of Sciences Potential Pathophysiological Mechanisms in Osteonecrosis of the Jaw , 2022 .